ID: MRFR/MED/4342-HCR | February 2021 | Region: Global | 100 pages
It is Estimated that the Head and Neck Cancer Market is expected to grow at a CAGR of 9.5% during the forecast period of 2017–2023.
Head and neck cancer begin in squamous cells that line the mucosal surfaces of the head and neck such as, inside the mouth, the nose, and the throat. The head and neck cancers include specific areas of the body such as oral cavity, pharynx, larynx, paranasal sinuses and nasal cavity, and salivary glands. Alcohol and tobacco are the two most common risk factors for head and neck cancers. Other risk factors for head and neck cancers include consumption of preserved or salted foods, occupational exposure to wood dust, Epstein-Barr virus infection, and poor oral hygiene. It is noted that the rising prevalence of head and neck cancers is the key factor driving the head and neck cancer market.
According to the 2014 statistics suggested by the World Health Organization (WHO), the annual occurrence rate of head and neck cancer is more than 550,000 cases with nearly 300,000 deaths each year, worldwide. Around 90% of the head and neck cancers are squamous cell carcinomas, and they are also the sixth leading cancer by occurrence worldwide.
In the United States, the head and neck cancer accounts for 3% of malignancies, i.e., around 63,000 Americans developing head and neck cancer annually, and 13,000 dying of this disease. In Europe, there were approximately 250,000 cases of cancer registered and 63,500 deaths in 2012.
Various other factors such as growing geriatric population, huge research funding in oncology, unmet medical needs, rising competition among market players, improving regulatory framework, aging population, and increasing government assistance are continuously contributing to the growth of the global head and neck cancer market.
According to a study published in the Cancer and Metastasis Reviews in 2017, the risk for head and neck squamous cell carcinoma in smokers is nearly ten times higher than that of non-smokers, and the diagnosis of 70 to 80% of new head and neck squamous cells is associated with the consumption tobacco and alcohol.
Despite these drivers, there are some issues associated with the head and neck cancer market. The high cost associated with treatment approach, side effects of available treatment options, lack of healthcare coverage, and poor healthcare system in low- and middle-income countries may hamper the growth of the market.
Head and Neck Cancer Market Segmentation
The head and neck cancer drugs market is segmented on the basis of the type of head and neck cancer diagnosis, treatment type, and end-user.
On the basis of the type of head and neck cancer market is classified as laryngeal cancer, pharyngeal cancer, salivary gland cancer, lip and oral cavity cancer, nasopharyngeal cancer, and others.
On the basis of diagnosis, the market is classified as bioscopy screening tests, blood tests, dental diagnosis, imaging, and endoscopy. The bioscopy screening tests are further classified as incisional biopsy, fine needle aspiration biopsy, and HPV testing. The blood tests are further classified as total cell count tests, liver function tests, and EBV antibody measurement. The dental diagnosis is further classified as fluorescence visualization, toluidine blue dye-based method, acetic acid rinse method, and brush biopsy. The imaging is further classified as PET/CT, MRI, X-ray, and Barium Swallow test. The endoscopy is further classified as pharyngoscopy, laryngoscopy, and others.
On the basis of treatment type, the head and neck cancer market is classified as chemotherapy, surgery, radiation therapy, targeted therapy, and others. The radiation therapy is further classified as external beam radiation and internal radiation therapy.
On the basis of end-user, the market is classified as hospitals, specialty clinics, and ambulatory surgical centers.
Sources: Annual reports, Press release, White paper, and Company presentation
Head and Neck Cancer Market Regional Analysis
The Americas dominate the head and neck cancer market owing to the presence of patient population, increasing prevalence of head and neck cancer, well-developed technology, high healthcare expenditure, and the presence of leading market players. The head and neck cancer accounts for nearly 3% of all the cancers in the United States. In 2017, around 63,030 people developed head and neck cancer.
Europe holds the second position in the head and neck cancer drugs market. It is expected that the research and development expenditure provided by the government and private associations, increasing competition among marketers, rising healthcare expenditure, and amendments in reimbursement policies in healthcare are likely to drive the European head and neck cancer market.
Asia Pacific is the fastest growing market owing to a huge patient pool, increasing demand, and development of the healthcare technology.
The Middle East and Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.
Head and Neck Cancer Market Key Players
Some of the key players in the global head and neck cancer market are AB Science SA, AbbVie Inc., Acceleron Pharma, Inc., AdDent Inc., ASAHI Roentgen, Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Carestream, Fujifilm Holdings, GE Healthcare, Identafi, Koninklijke Philips N.V., NeuSoft, Shimadzu Corporation, Siemens Healthcare, Varian Medical Systems, Xoran, and others.
Frequently Asked Questions (FAQ) :
Major types of head and neck cancer include salivary gland, laryngeal, pharyngeal, oral cavity, and nasopharyngeal.
Global Market is expected to exhibit a strong 9.5% CAGR over the forecast period from 2017 to 2023.
Growing awareness about cancer is the major driver for the Head and Neck Cancer drugs Market.
The Americas dominate the Global Market.
Leading players in the Market include AbbVie, Boston Biomedical, and Bayer AG, among others.